PF-05251749 complements the company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases. Biogen has agreed to acquire from...

Web-based platform provides broad access to the first-ever cloud laboratory to integrate automated biology and chemistry research capabilities in a closed-loop syste...

Multiple options provide increased flexibility for sponsors. Catalent has launched FlexDirect, a new direct-to-patient service for clinical trials. The FlexDirect ...

After last year’s unexpected passing of founder and long-time helmsman Thomas Neff, FibroGen needed a permanent successor—and with its big roxadustat launch looming,...

Tidying up business left from last year, Bristol-Myers Squibb has completed the sale of an old-school operation in Italy even as it prepares to move into a whole new...

Amarin scored a massive win last month after the FDA approved its fish-oil derivative Vascepa as a heart-helping addition to statins, potentially setting the drug up...

Johnson & Johnson just got some new ammo for its defense against lawsuits claiming its talc products caused ovarian cancer. As the company fights with plaintif...

Less than a year after buying a U.S. plant from AstraZeneca, Novartis’ biotech AveXis has it ready for production of Zolgensma, its gene therapy for spinal muscular ...

The U.S. Food and Drug Administration today granted accelerated approval to Vyondys 53 (golodirsen) injection to treat Duchenne muscular dystrophy (DMD) patients wh...

AstraZeneca has completed an agreement to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate exte...